Researchers at Carnegie Mellon University have developed a groundbreaking lens technology that enables a camera to focus on ...

As of Monday, December 29, Aligos Therapeutics, Inc.’s ALGS share price has dipped by 5.24%, which has investors questioning ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

A new microchip-sized device could dramatically accelerate the future of quantum computing. It controls laser frequencies ...

This move represented a sharp increase in price on volume nearly 3x the average daily trading volume, indicating robust ...

Edgewise Therapeutics (EWTX) announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel oral, selective, ...

“Photon Design's next-generation, EPIPPROP simulator, will offer the flexibility to split waveguides, simulating this process ...

Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified ...

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...

D Molecular Therapeutics (FDMT) stock slips as the company posts early-stage trial data for its cystic fibrosis drug 4D-710.